MARKET

PTN

PTN

PALATIN TECH
AMEX

Real-time Quotes | Nasdaq Last Sale

0.7666
-0.0244
-3.08%
After Hours: 0.7660 -0.0006 -0.08% 16:29 03/03 EST
OPEN
0.8000
PREV CLOSE
0.7910
HIGH
0.8010
LOW
0.7600
VOLUME
3.89M
TURNOVER
--
52 WEEK HIGH
1.300
52 WEEK LOW
0.3550
MARKET CAP
176.34M
P/E (TTM)
-6.7961
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Melanocortin Receptor 4 Market Development, Market Trends, Key Driven Factors, Segmentation and Forecast 2020-2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 01:39:22 / Comserve Inc. / -- Melanocortin Receptor 4 market is segmented by Type, and by Application. Players, stakeholders,...
Comserve · 02/22 06:40
Palatin Technologies (PTN) Received its Third Buy in a Row
SmarterAnalyst · 02/18 11:46
H.C. Wainwright Maintains a Buy Rating on Palatin Technologies (PTN)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Palatin Technologies (PTN) today and set a price target of $2.00. The company's shares
SmarterAnalyst · 02/18 11:18
Palatin Technologies (PTN) Receives a Buy from Canaccord Genuity
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Palatin Technologies (PTN), with a price target of $3.00.
SmarterAnalyst · 02/18 11:07
Melanocortin Receptor 4 Market 2021: COVID-19 Impact, Growing Rapidly with Modern Trends, Development, Size, Share, Revenue, Demand and Forecast to 2027
Feb 18, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Melanocortin Receptor 4...
The Express Wire · 02/18 05:22
Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Lags Revenue Estimates
Zacks.com · 02/18 01:37
DJ Palatin Technologies' CEO Carl Spana on Q2 2021 Results -- Earnings Call Transcript >PTN
Dow Jones · 02/17 21:29
EH, PTN, ONTX and SHIP among midday movers
Gainers: CLPS (CLPS) +275%.Comstock Mining (LODE) +176%.TDH Holdings (PETZ) +134%.Dogness (DOGZ) +54%.Onconova Therapeutics (ONTX) +50%.EHang (EH) +42%.Processa Pharmaceuticals (PCSA) +34%.ZW Data Action Technologies (CNET) +33%.Ebang International (EBON) ...
Seekingalpha · 02/17 17:40
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTN. Analyze the recent business situations of PALATIN TECH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTN stock price target is 2.333 with a high estimate of 3.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 44.69M
% Owned: 19.43%
Shares Outstanding: 230.03M
TypeInstitutionsShares
Increased
32
4.81M
New
20
1.36M
Decreased
17
1.34M
Sold Out
6
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-4.15%
Pharmaceuticals & Medical Research
-1.98%
Key Executives
Chairman/Independent Director
John Prendergast
President/Chief Executive Officer/Director
Carl Spana
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
Stephen Wills
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
stephen Wills
Independent Director
Robert deVeer
Independent Director
Alan Dunton
Independent Director
Joseph Hull
Independent Director
Anthony Manning
Independent Director
Arlene Morris
  • Dividends
  • Splits
  • Insider Activity
No Data
About PTN
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.

Webull offers kinds of Palatin Technologies, Inc. stock information, including AMEX:PTN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTN stock methods without spending real money on the virtual paper trading platform.